18:18 , Oct 12, 2018 |  BC Week In Review  |  Financial News

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million on Oct. 10 through the sale of 5.2 million shares at $29 in a follow-on underwritten by...
05:03 , Oct 11, 2018 |  BC Extra  |  Financial News

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million Wednesday through the sale of 5.2 million shares at $29 in a follow-on underwritten by BofA Merrill...
18:26 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Audentes reports Phase I/II muscle biopsy data for myopathy gene therapy

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported data from its 24-week muscle biopsy analyses of the first dose cohort and said an IDMC recommended proceeding to the second dose cohort of the Phase I/II ASPIRO trial evaluating...
15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Audentes reports updated Phase I/II myopathy data for AT132

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported updated interim data from the first cohort of the open-label, dose-escalation, U.S. Phase I/II ASPIRO trial testing AT132 in patients with X-linked myotubular myopathy (XLMTM). The presentation at the American...
20:57 , May 18, 2018 |  BC Extra  |  Clinical News

Audentes rises on additional myopathy data

Audentes Therapeutics Inc. (NASDAQ:BOLD) ended the week at $38.24, up $4.04 (12%), after an oral presentation of updated interim data from the first cohort of the dose-escalation Phase I/II ASPIRO trial testing AT132 in patients...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
21:50 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Audentes reports interim Phase I/II data for XLMTM candidate

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) reported interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy, a rare monogenic disease characterized by extreme muscle...
22:28 , Jan 4, 2018 |  BC Extra  |  Clinical News

Audentes gains on XLMTM readout

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $5.28 (15%) to $40.81 on Thursday after reporting interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy,...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...